CMS Star Ratings Unreliable for Surgical Quality?


Higher ratings tied to better surgical outcomes, but variability was high even within star groups

by
Michael DePeau-Wilson,

Enterprise & Investigative Writer, MedPage Today

June 18, 2024

Higher CMS hospital star ratings generally were associated with better surgical outcomes, but there was wide variability within each star-rating group, suggesting its utility for assessing surgical quality may be limited, according to a cohort study.

In an analysis of 3,240 CMS star-rated hospitals, 30-day mortality rates fell from 6.80% for 1-star hospitals to 4.93% for 5-star hospitals (adjusted OR 1.86, 95% CI 1.73-2.00), and similar trends were observed for complication rates, serious complication rates, and 30-day readmission, Adrian Diaz, MD, MPH, of The Ohio State University, and colleagues reported in JAMA Surgery.

However, there was wide variation in these outcomes when comparing the top and bottom 5% of hospitals — even within star-ratings groups. For instance, mortality varied nearly two-fold for each group:

  • 1 star: 1.91% (3.6%-12%)
  • 2 star: 1.86% (2.8%-16.2%)
  • 3 star: 1.84% (2.9%-12.3%)
  • 4 star: 1.76% (2.9%-11.5%)
  • 5 star: 1.79% (2.4%-9.1%)

Once again, similar trends in variation were observed for complications, serious complications, and readmissions, they reported.

“The star rating system is publicly available [and] it’s widely used, but it’s probably not the best tool for patients to pick the hospital to have surgery or to pick the surgeon that’s going to do their operation,” Diaz told MedPage Today. “It’s just not robust or specific enough for that.”

CMS first released its hospital star ratings program in 2016 to establish a public database of hospital quality. It was met with controversy, however, as experts cited methodologic limitations. The program was paused in 2020 for evaluation, and a revised version was released in 2021.

Diaz said this study is the first to evaluate surgery-specific outcomes with the revised ratings.

Many 5-star hospitals had higher rates of adverse post-surgical outcomes than hospitals with lower star ratings, even in the same geographic regions, Diaz noted. That suggests the CMS star rating system may not adequately inform patients about the quality of specific operations at any given hospital, he said.

Publicly available procedure-level data could help patients decide which hospital to choose for their specific health needs, Diaz added.

“[Patients] should be able to hit the search button … and the data should be able to tell [them] these are your options. These are those surgeons’ and those hospitals’ outcomes, and based on your preferences, these are your top three choices,” Diaz said. “Nothing like that exists for patients to make those decisions, but I think the data is available and we have the tools to make that possible.”

In an invited commentary, Anoosha Moturu, MD, of the American College of Surgeons (ACS), and colleagues noted that evaluating surgical quality is difficult for many reasons, including the fact that the “source of data most used for evaluating quality is suboptimal. The CMS and other benchmarking organizations use claims data … for many of their metrics, which has been shown to be inferior to clinical data for reporting surgical outcomes.”

They added that ACS has started to address these deficiencies by developing a public reporting site and compiling metrics that are “based on lessons from decades of leading surgical quality of care measurement, standards development, accreditation, and improvement.”

For their analysis, Diaz and colleagues analyzed data on 1,898,829 Medicare beneficiaries who had either colectomy, coronary artery bypass graft, cholecystectomy, appendectomy, or incisional hernia repair at 3,240 nonfederal acute care hospitals with a CMS hospital star rating from 2014 to 2018.

Overall, patients had a mean age of 74.8 years, 50.6% were male, and 86.5% identified as white.

The study was limited by only including Medicare patients, who tend to be older and sicker than the general population. Also, the dataset did not include any patients on Medicare Advantage plans, further limiting its generalizability.

Diaz urged clinicians to “write to CMS, write to their representatives,” to “get this stuff out there.”

“The reason the rating system was revised over a year ago was because of providers like us — and others around the country — who have demonstrated this is an imperfect system,” he said. “It’s continued to be imperfect, but there’s ways that we can strive to make it better.”

  • author['full_name']

    Michael DePeau-Wilson is a reporter on MedPage Today’s enterprise & investigative team. He covers psychiatry, long covid, and infectious diseases, among other relevant U.S. clinical news. Follow

Disclosures

The study was funded by the NIH, the University of Michigan Institute for Healthcare Policy and Innovation Clinician Scholars Program, and the Agency for Healthcare Research and Quality (AHRQ).

Authors reported financial relationships with the NIH, the University of Michigan Institute for Healthcare Policy and Innovation Clinician Scholars Program, AHRQ, and ArborMetrix.

The editorialists reported no conflicts of interest.

Primary Source

JAMA Surgery

Source Reference: Diaz A, et al “Variation in postoperative outcomes across federally designated hospital star ratings” JAMA Surg 2024; DOI: 10.1001/jamasurg.2024.1582.

Secondary Source

JAMA Surgery

Source Reference: Moturu A, et al “The American College of Surgeons approach to public reporting” JAMA Surg 2024; DOI: 10.1001/jamasurg.2024.1591.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis thumbnail

FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis

The US Food and Drug Administration (FDA) today approved risankizumab-rzaa (Skyrizi) for a second indication — treating adults with active psoriatic arthritis (PsA) — making it the second anti-interleukin 23 monoclonal antibody available to treat PsA, according to an announcement from manufacturer AbbVie. The agency previously approved risankizumab in April 2019 for adults with moderate-to-severe…
Read More
All private hospitals in Singapore to connect to national EMR thumbnail

All private hospitals in Singapore to connect to national EMR

The Ministry of Health Singapore has announced that all nine private hospitals in the country have committed to sharing patient health information with the National Electronic Health Record system.  They will be working with Synapxe, which manages the NEHR, to get their hospital management systems prepared for integration by next year, according to a media statement.  
Read More
ASCVD Mortality Linked to Specific Air Pollution Sources thumbnail

ASCVD Mortality Linked to Specific Air Pollution Sources

Public Health & Policy > Environmental Health — Pollution-mortality relationship evidenced at the level of PM2.5 source type by Nicole Lou, Senior Staff Writer, MedPage Today November 27, 2024 Different components of small particular matter linked to modest cardiovascular effects.Relationship persisted even in neighborhoods meeting the current National Ambient Air Quality Standard for small particular
Read More
Voice-control smart devices might hinder kids' social and emotional development, says expert thumbnail

Voice-control smart devices might hinder kids’ social and emotional development, says expert

Credit: Unsplash/CC0 Public Domain Voice-control smart devices, such as Alexa, Siri, and Google Home might hinder children's social and emotional development, argues an expert in the use of artificial intelligence and machine learning in health care, in a viewpoint published online in the Archives of Disease in Childhood. These devices might have long-term effects by
Read More
Index Of News
Total
0
Share